全文获取类型
收费全文 | 908篇 |
免费 | 52篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 45篇 |
妇产科学 | 3篇 |
基础医学 | 98篇 |
口腔科学 | 17篇 |
临床医学 | 77篇 |
内科学 | 239篇 |
皮肤病学 | 3篇 |
神经病学 | 13篇 |
特种医学 | 315篇 |
外科学 | 60篇 |
综合类 | 13篇 |
预防医学 | 28篇 |
眼科学 | 5篇 |
药学 | 31篇 |
中国医学 | 1篇 |
肿瘤学 | 36篇 |
出版年
2022年 | 2篇 |
2021年 | 11篇 |
2020年 | 5篇 |
2019年 | 5篇 |
2018年 | 18篇 |
2017年 | 4篇 |
2016年 | 9篇 |
2015年 | 9篇 |
2014年 | 9篇 |
2013年 | 8篇 |
2012年 | 23篇 |
2011年 | 21篇 |
2010年 | 17篇 |
2009年 | 20篇 |
2008年 | 12篇 |
2007年 | 30篇 |
2006年 | 21篇 |
2005年 | 13篇 |
2004年 | 14篇 |
2003年 | 12篇 |
2002年 | 17篇 |
2001年 | 13篇 |
2000年 | 9篇 |
1999年 | 17篇 |
1998年 | 47篇 |
1997年 | 40篇 |
1996年 | 59篇 |
1995年 | 45篇 |
1994年 | 34篇 |
1993年 | 43篇 |
1992年 | 15篇 |
1991年 | 12篇 |
1990年 | 15篇 |
1989年 | 34篇 |
1988年 | 40篇 |
1987年 | 31篇 |
1986年 | 26篇 |
1985年 | 40篇 |
1984年 | 21篇 |
1983年 | 24篇 |
1982年 | 28篇 |
1981年 | 26篇 |
1980年 | 12篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1977年 | 26篇 |
1976年 | 18篇 |
1975年 | 14篇 |
1969年 | 2篇 |
1961年 | 1篇 |
排序方式: 共有985条查询结果,搜索用时 15 毫秒
51.
52.
鸟氨酸脱羧酶的生理病理特点及其药物研究概况 总被引:2,自引:0,他引:2
鸟氨酸脱羧酶(ornithinedecarboxylase,ODC)是多胺代谢中的关键酶,广泛存在于人体和动物各组织细胞内,其中对肠细胞的增生、移行和分化起重要作用.机体调节因素比较复杂.在黏膜损伤性疾病及某些癌前病变等细胞大量增生的病理情况下ODC的表达发生改变,可以作为这些疾病分期、预后及药物作用靶点或疗效的指标.寻找对ODC有作用的药物对于治疗其相关疾病是非常有意义的. 相似文献
53.
54.
目的:分析血管紧张素原基因启动子区A-20C和A-6G单核苷酸多态性与蒙古族人群原发性高血压的相关性。方法:实验于2005-08/2006-01在北京华大实验室完成。选取对象均为生活在内蒙古乌拉特后旗的蒙古族牧民,三代血亲内无其他民族。采用基因测序技术对内蒙古蒙古族人群中107例原发性高血压患者和108例正常对照者进行A-20C和A-6G基因分型,观察高血压组和正常对照组不同基因型的分布和等位基因频率的差异。结果:①两组受试者在性别、年龄及吸烟、饮酒、体质量指数和临床化验检查指标有较好的匹配(P均>0.05)。②两组血管紧张素原基因A-20C位点AA,AC,CC基因型频率比较差异无显著性意义(高血压组分别为0.51,0.29,0.20;正常对照组分别为0.49,0.28,0.23,χ2=0.395,P=0.529)。A,C等位基因频率比较差异无显著性意义(高血压组分别为0.65,0.35;正常对照组分别为0.63,0.37,χ2=0.015,P=0.904)。③两组血管紧张素原基因A-6G位点AA,AG,GG基因型频率比较差异无显著性意义(高血压组分别为0.50,0.33,0.17;正常对照组分别为0.55,0.34,0.11,χ2=1.924,P=0.165)。A,G等位基因频率比较差异无显著性意义(高血压组分别为0.66,0.34;正常对照组分别为0.72,0.28,χ2=1.728,P=0.189)。④高血压组协同存在血管紧张素原基因A-20C基因型CC时,血管紧张素原基因A-6G基因型GG频率稍高于正常对照组,但差异无显著性意义(χ2=2.395,P=0.122,OR=7.52,95%CI0.014~1.250),高血压组G等位基因明显高于正常对照组(分别为0.37,0.22,χ2=4.658,P=0.034),携带该等位基因的蒙古族人群发生原发性高血压的相对危险度升高(OR=2.80,95%CI1.087~7.271)。结论:血管紧张素原基因A-20C和A-6G单核苷酸多态性与蒙古族人群原发性高血压相关,并可能具有协同作用。 相似文献
55.
HYPOTHESIS: Central pancreatectomy has been used sparingly because the spectrum of indications is quite narrow. Although historically used for traumatic pancreatic transection and chronic pancreatitis, it currently is reserved for selective management of pancreatic neck lesions that are benign or have low malignant potential. Varying morbidity rates have been published in the literature. Our objectives were to describe the technique and determine the safety and effectiveness of central pancreatectomy in the excision of benign or low-malignant potential lesions of the pancreatic neck. DESIGN: Retrospective clinicopathologic data review. SETTING: The Mayo Clinic surgical index was used to identify procedures matched for central, median, middle, or middle segment pancreatectomy. PATIENTS: Eight patients (4 men, 4 women) underwent central pancreatectomy between 1998 and 2004. INTERVENTION: Patients with pancreatic neck or proximal body masses underwent central pancreatectomy at the Mayo Clinic, Rochester, Minn. MAIN OUTCOME MEASURES: Patients were followed up closely for postoperative complications during the initial hospital admission. On follow-up, long-term endocrine and exocrine function were determined based on laboratory values and patient history. RESULTS: Abnormalities included 3 islet cell tumors, 2 serous cystadenomas, a mucinous cystadenoma, a lymphoepithelial cyst, and a recurrent liposarcoma. Mean tumor size was 2.8 cm and mean operative time was 4.8 hours with a mean blood loss of 381 mL. The most common complication was pancreatic leak (5 patients [63%]). Reoperation was necessary in 2 patients (25%), both secondary to hemorrhage. There was no mortality or new-onset diabetes mellitus. One patient transiently required oral pancreatic enzyme supplementation. CONCLUSIONS: Central pancreatectomy may preserve endocrine and exocrine function. While mortality is low, in our experience, central pancreatectomy is associated with a high complication rate. The most common complication is pancreatic leak. Caution is necessary when using central pancreatectomy in the treatment of pancreatic neck lesions. Surgeon experience is of utmost importance in this decision-making process as well as the technical aspects of central pancreatectomy. The precise role of central pancreatectomy in the management of benign or low-malignant potential lesions of the neck of the pancreas remains in evolution. 相似文献
56.
57.
58.
ER Brown KA Charles SA Hoare RL Rye DI Jodrell RE Aird R Vora U Prabhakar M Nakada RE Corringham M DeWitte C Sturgeon D Propper FR Balkwill JF Smyth 《Annals of oncology》2008,19(7):1340-1346
BACKGROUND: Tumour necrosis factor-alpha (TNF-alpha) is an important regulator of the chronic inflammation contributing to tumour progression. Infliximab, an anti-TNF-alpha monoclonal antibody was investigated in this trial of patients with advanced cancer. The primary objectives were to determine the safety profile and biological response of infliximab in a cancer population. Clinical response was a secondary objective. PATIENTS AND METHODS: Forty-one patients received infliximab at 5 mg/kg (n = 21) or 10 mg/kg (n = 20) i.v. at 0 and 2 weeks and then every 4 weeks. Post-treatment samples were measured for changes in plasma and serum TNF-alpha, CCL2, IL-6 and C-reactive protein (CRP). RESULTS: Infliximab was well tolerated with no dose-limiting toxic effects. At both doses of infliximab, neutralisation of serum TNF-alpha was observed after 1 h while plasma CCL2, IL-6 and serum CRP were decreased 24 and 48 h following infliximab administration. Seven patients experienced disease stablisation (range 10-50+ weeks). There was no evidence of disease acceleration in any patient. CONCLUSIONS: Infliximab treatment was safe and well tolerated in patients with advanced cancer. There was evidence of biological activity with baseline TNF-alpha and CCL2 being correlated with infliximab response. 相似文献
59.
60.